Company ProfilePremium

Vestaron Corporation

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Vestaron Corporation - Company showcase

Year Founded & Workforce

2005

25 Employees

Vestaron Corporation logo

Vestaron Corporation Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Vestaron Corporation Overview

Vestaron Corporation was an early commercial pioneer of peptide-based bioinsecticides. These are crop protection products built from insecticidal peptides that originally came from spider venom, optimised by the company and produced through microbial (yeast) fermentation. Its lead active, the SPEAR® peptide, received a new Insecticide Resistance Action Committee mode-of-action classification (IRAC Group 32). That classification places the active at the nicotinic acetylcholine receptor but at a different binding site from neonicotinoids and spinosyns. Vestaron positioned its products as matching the efficacy of conventional synthetics while offering a biological's safety profile: a 4-hour re-entry interval, a 0-day pre-harvest interval, MRL exemption, and low toxicity to pollinators and beneficial insects. After launching SPEAR products in the U.S. from 2018–2020, the company expanded into Canada, Mexico and EU emergency-use markets, and registered a second active, BASIN™, in 2024. In May 2026 Suterra acquired its product and R&D assets, which effectively ended Vestaron's life as an independent commercial operator.


What the company does

Vestaron discovered, optimised, registered and commercialised peptide insecticides. Peptides are short chains of amino acids, smaller than proteins. Its proprietary process starts with natural insecticidal peptides found in spider venom and other venomous animals, then modifies them. Production runs through fermentation (Techleap/citybiz profile, March 2025; Packer, June 2026). The company's long-standing thesis is the following:

  • Six key muscle and nerve receptors account for about 80% of the global insecticide market. Vestaron said in 2022 that it had peptides in its pipeline suited to all six (Global AgInvesting, May 2022).

  • The nicotinic acetylcholine receptor, which SPEAR targets, accounts for about 30% of the roughly USD 18 billion global insecticide market (company-cited figure, repeated across 2019–2022 releases).

  • Peptides can hit validated neuromuscular targets at new binding sites. This avoids cross-resistance with incumbent chemistries while keeping a biological's residue and safety profile.

Company's own description

Recent boilerplate describes Vestaron as leading a global revolution in crop protection by creating novel, effective and sustainable solutions for growers facing the challenges of modern agriculture. It also notes that Vestaron was the first agriculture and food company inducted into the Global CleanTech 100 Hall of Fame (GlobeNewswire, July 2025). Earlier boilerplate (2019) called Vestaron "The Peptide Company." It described the mission as improving the safety, efficacy and sustainability of crop protection by migrating from chemical pesticides to biological peptides (MEDC, April 2019). Vestaron has no annual report because it is private, so this description is taken from press boilerplate.

Business model and revenue model

DimensionCharacterisationEvidence
Revenue typeAlmost entirely product sales of formulated end-use insecticides. No subscription revenue. Licensing/royalty revenue not disclosedPreqin describes a direct-sales model around SPEAR and BASIN
PricingSPEAR LEP priced at parity with conventional synthetic chemistriesIBMA interview (2025)
Route to marketOwn territory managers plus regional distribution partners (e.g., Wilbur-Ellis in the U.S.; Oxygen AgroShield in Greece; Premier Shukuroglou in Cyprus; Lainco in Iberia)Vegetable Growers News (Nov 2021); Farm Progress; GlobeNewswire (2024–2025)
ManufacturingOutsourced fermentation: first Capua BioServices (Italy), then a long-term agreement with ADM from October 2024AgriBusiness Global; GlobeNewswire (15 Oct 2024)
Product/service mixProduct ~100%; service revenue n/dAnalyst characterisation

Value-chain position

Vestaron sat at the active-ingredient discovery and branded end-product layer of the crop protection value chain. It was asset-light in manufacturing, relying on contract fermentation, and channel-dependent in distribution. It sold through agricultural retail and distributors to growers. It did not own retail or large-scale manufacturing.

Customer types and end-markets

End-marketCrops / pestsProducts
Specialty field crops (core)Tree nuts (pistachio, almond: navel orangeworm), grapes, stone fruit, vegetables (crucifers, tomato, pepper), apples (codling moth)SPEAR LEP, BASIN FLEX, LEPROTEC
Protected agriculture / greenhousesThrips, whiteflies, aphids, mitesSPEAR T
Broad-acre row cropsCotton (bollworm), soybean (looper), rice, armywormsSPEAR RC
EU emergency-use marketsTomato (Tuta absoluta), olive (Prays oleae)SPEAR LEP under Article 53 EUAs
Organic productionBt-based caterpillar controlLEPROTEC (OMRI listed)

Early-stage plans (c.2012) also targeted animal health, public health and lawn & garden, then sized by the company at a combined USD 15.4 billion (Xconomy). No commercial activity in these non-crop markets has been publicly documented.

Independent characterisation

Vestaron was a technically successful but commercially sub-scale biological insecticide innovator. It achieved the hardest milestones in the category: novel IRAC classification, EPA registration of two new active ingredients, multi-country approvals, a cumulative footprint above one million treated acres, and blue-chip strategic investors. However, it never reached disclosed profitability or the scale needed to fund global registration (EU approval was still pending, targeted for 2027) on its own. The May 2026 sale to a vertically integrated strategic buyer is the classic end-game for venture-funded ag-input innovators. Its IP becomes a portfolio extension for a player with manufacturing scale and global registrations.

Strategy

Stated strategic themes (from releases 2022–2025)

  1. Peptide platform breadth. Build a family of peptides, each with a novel mode of action, across the six key neuromuscular receptors (Series C release, 2022).

  2. Geographic expansion. Use new capital for new geographies, with Europe as a priority market given synthetic-pesticide restrictions (2019, 2022 and 2025 releases).

  3. Crop expansion. Move from specialty crops into broad-acre row crops and new pest categories (Grosvenor add-on, 2022; SPEAR RC launch, 2023).

  4. Cost and scale. Secure stable, scalable, lower-cost fermentation supply (ADM agreement, Oct 2024).

  5. Regulatory advocacy in the EU. A twofold approach (IBMA interview, 2025): lobby EU policymakers for a faster and more suitable approval pathway for peptide biopesticides, and support grower-led EUA petitions in the meantime.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDetail
Oct 2024ADM manufacturing collaborationLong-term production agreement with ADM's precision fermentation unit
Mar 2025Growth financingMore than USD 20M raised to accelerate commercialisation in the U.S. and Europe
2,025EU EUA expansionSecond-cycle EUAs (IT/GR/CY), new Portugal EUA, new crop (olive in Italy)
Jul 2025Lainco partnership (Iberia)Spanish agrochemical company (90-year history) as European commercial partner
May 2026Strategic exitSale of product lines, actives, pipeline and R&D assets to Suterra

ESG / sustainability commitments

Positioning centres on pollinator safety, worker safety (4-hour REI), biodiversity and reduced synthetic use. No quantified emissions targets were found.

Medium-term targets / guidance

None disclosed, other than a company statement that EU full approval of SPEAR LEP was hoped for in 2027 (IBMA, 2025). After the asset sale, this milestone now falls to Suterra.

Products & Services

All products below were Vestaron-owned until the May 2026 Suterra acquisition. Ownership of SPEAR and BASIN lines has since passed to Suterra.

SPEAR® LEP

AttributeDetail
DescriptionPeptide-based bioinsecticide for lepidopteran larvae (caterpillars, loopers, worms) in field crops
Active / MoASPEAR peptide. IRAC Group 32. Acts on the nicotinic acetylcholine receptor at a site distinct from neonicotinoids and spinosad. No known resistance or cross-resistance
Key label attributes4-hour REI, 0-day PHI, MRL exempt, practically non-toxic to pollinators. No special handling/storage
Usage noteDesigned to be tank-mixed with Bt products. Bt disrupts the larval midgut and lets the peptide reach nervous-system targets (Farm Progress; Knowde)
Target cropsTree nuts (navel orangeworm), apples (codling moth), grapes (European grapevine moth), vegetables, tomato
RegistrationU.S. full approval 2018; registered in all 50 states. Commercial launch 2020. Canada (in use since 2020). Mexico (Nov 2021). EU dossier filed 2022, approval hoped for 2027
EU EUAsGreece (2024, 2025, fourth in Jul 2025), Italy (2024, 2025; olives 2025), Cyprus (2024, 2025), Portugal (Jul 2025)
PricingParity with conventional synthetics (IBMA)
EUA use rate (Greece)3 applications every 5–15 days at 1–2 L/ha

SPEAR® T Liquid Concentrate

AttributeDetail
DescriptionGreenhouse bioinsecticide
Target pestsAll four major greenhouse pests: thrips, whiteflies, aphids, mites
RegistrationFirst EPA-approved Vestaron biopesticide (2018)
Target customerGreenhouse vegetable and ornamental growers

SPEAR® RC

AttributeDetail
DescriptionSPEAR formulation positioned for broad-acre row crops
Target pestsCotton bollworm, soybean looper, armyworm
CropsCotton, soybean, rice, other broad-acre crops
LaunchIntroduced to growers at early-2023 conferences (Mid-South Farm & Gin Show, Commodity Classic)
AttributesIRAC 32, 0-day PHI, 4-hour REI, MRL exempt

BASIN™ / BASIN™ FLEX

AttributeDetail
DescriptionVestaron's second peptide active ingredient, derived from modified spider venom
MoATargets the same receptor as SPEAR but at another site
Target pestsLepidoptera in stone fruit, tree nuts, vegetables, specialty crops
Attributes4-hour REI, 0-day PHI, MRL exemption
RegulatoryEPA submission 15 Mar 2022 (Q4 2022 launch was targeted then but slipped). EPA unconditional registration Mar 2024. COFEPRIS AI registration 22 Mar 2024. Some aggregators reported earlier Mexico approval (sp-edge), a discrepancy
Commercial launchExpected in or before 2025 (company, Mar 2024). Actual launch date n/d; product was described as "upcoming" in 2025 aggregator profiles

LEPROTEC® (liquid)

AttributeDetail
DescriptionLiquid formulation of Bacillus thuringiensis subsp. kurstaki strain EVB-113-19
TargetLoopers, worms, caterpillars in outdoor food, non-food and greenhouse crops
PositioningOMRI listed (organic). Designed as the companion to SPEAR LEP
SourceGlobal AgInvesting (May 2022); Knowde

LEPROTEC® WG

AttributeDetail
DescriptionWater-dispersible granule variant of LEPROTEC (Btk)
DetailSpecifications n/d beyond listing on vestaron.com product menu

Pipeline (transferred to Suterra)

  • Additional active ingredients and product formulations under development were included in the Suterra sale (Suterra, May 2026).

  • In 2022 the company claimed pipeline peptides addressing all six major insecticidal neuromuscular receptors (Global AgInvesting).

  • In early 2014 the company reported more than 50 unique spider-venom peptides with novel sites of action identified (Xconomy funding feed).

  • Historic trait ambitions: the platform was described as supporting both sprayable products and insect-resistant crop traits (MEDC 2019; Global AgInvesting 2022). No trait product has been commercialised.

Financial Narrative

Vestaron is private and has not published audited financial statements, revenue, profit or balance-sheet data for any year. Every line item below is therefore "n/d". The tables are kept to preserve the dossier structure for automated capture.

Income statement

Note on dividends: no dividends have ever been reported. Zero is shown because venture-backed preferred-stock companies at this stage do not pay dividends. Treat as analyst inference.

Margins (%)

Revenue CAGR FY2021–FY2025: n/d.

Disclosed capital-raising data (the only verifiable financial series)

Sources: Series B-1 USD 18M (Novo Holdings, Feb 2021); Series C USD 82M plus USD 10M add-on (Global AgInvesting; NCBiotech, 2022); round of more than USD 20M (Techleap/citybiz; Preqin, Mar 2025). Dealroom lists further late-stage tranches of USD 18.3M and USD 61.2M whose dates and relationship to the rounds above could not be reconciled. This is a source discrepancy.

Commentary on trends, inflections and drivers

Without reported financials, the analysis must rely on proxies:

Funding cadence as a burn proxy: Vestaron raised about USD 130M in 2021–2022. It then went about 2.5 years without a publicly announced round, until the 2025 raise of just over USD 20M, a much smaller ticket. Reported Dealroom valuations rose from about USD 200M to about USD 410M. The step-down in round size, combined with a change of CEO in 2024 (CFO elevated to CEO), suggests a pivot from growth funding to capital discipline and runway extension. This is analyst inference.

Manufacturing cost inflection: The October 2024 ADM agreement was explicitly framed around scale and lower cost of goods sold, through access to bio-based feedstocks and fermentation capacity (i3/Cleantech Group summary; GlobeNewswire). This implies gross margin was a key constraint before 2024.

Commercial traction: Cumulative adoption passed 1 million acres by March 2025 (citybiz/Techleap). California pistachio share rose from 3% (2020) to 5% (2021). These are real but modest penetration numbers in a single, high-value niche.

End-state: The May 2026 asset sale to Suterra, with no disclosed price, is consistent with a company that had validated its technology but lacked the self-funded path to profitability and global registration. Deal value is n/d. Whether investors recovered their capital is unknown.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Operational Segment Details

Operational segment (analyst construct)ContentsProducts

Specialty Field Crops

Lepidopteran control in tree nuts, fruit, vegetables, vines

SPEAR LEP, BASIN FLEX, LEPROTEC, LEPROTEC WG

Protected Agriculture

Greenhouse sucking/rasping pests

SPEAR T Liquid Concentrate

Broad-Acre Row Crops

Cotton, soybean, rice lepidopterans

SPEAR RC

International (Mexico, Canada, EU EUAs)

Regional registrations and emergency-use sales

SPEAR LEP, BASIN (Mexico AI)

Revenue by Segment (%)

MetricFY2020FY2021

SPEAR share of California pistachio insecticide market (%)

35

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends per share (USD)

00000

Financial Analysis — Dividends paid

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (USD Mn)

00000

Share buybacks (USD Mn)

00000

Balance Sheet

MetricFY2021FY2022FY2025

Disclosed equity raised (USD Mn)

189220

Country Overview

CountryMarket statusFirst accessBasis

United States

Core market. SPEAR registered in all 50 states. BASIN registered 2024

2018 (SPEAR-T); 2020 (SPEAR LEP launch)

EPA registrations

Canada

SPEAR LEP in use

2,020

IBMA; AgriBusiness Global

Mexico

SPEAR-Lep registered; BASIN AI registered

Nov 2021; Mar 2024

COFEPRIS

Greece

EUAs (tomato), four granted by July 2025

Feb 2024

Article 53 EUA

Italy

EUAs (tomato; olive from 2025)

Mar 2024

Article 53 EUA

Cyprus

EUAs (tomato)

May 2024

Article 53 EUA

Portugal

EUA (tomato)

Jul 2025

Article 53 EUA

Spain, France

Country websites exist; commercial status n/d

—

vestaron.com

Brazil

Interest noted; no registration found

—

NCBiotech (2022)

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable (private)

Dividend history / policy

None paid

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

n/d. Only a 2014 SEC-reported debt raise of USD 1.27M is known

Exit

Asset sale to Suterra, May 2026. Consideration n/d

Capital Markets Data

MetricFY2025

Reported post-money valuation (USD Mn)

410

Analyst Conclusions

Management guidance

No financial guidance has ever been published. The last public operational guidance was the hoped-for 2027 EU approval of SPEAR LEP. Following the May 2026 sale, forward strategy belongs to Suterra. Suterra plans to manufacture its own branded SPEAR LEP in 2026, build IPM programmes combining pheromones with peptides, use its existing European and African registrations, and explore broad-acre partnerships in corn and cotton.

Consensus

None (private; no coverage).

Bull case (for the Vestaron technology under Suterra ownership)

  1. Faster international rollout. Suterra's vertically integrated manufacturing in Bend, Oregon and its registrations in more than 30 countries remove Vestaron's two biggest constraints: scale and global reach.

  2. Validated product. More than 1M acres treated and repeat EUAs in four EU countries show real demand.

  3. Large-acre upside. Broad-acre expansion (SPEAR RC; corn and cotton interest) could add revenue many times the specialty-crop base.

Bear case

  1. Equity value unknown. No deal price was disclosed. If the sale was distressed, Vestaron shareholders may have recovered little of more than USD 200M invested.

  2. Regulatory bottleneck remains. The EU process is still slow, so full EU value may not arrive before 2027 or later, regardless of owner.

  3. Integration risk. A pheromone-focused company must now master peptide fermentation and pipeline R&D, and key Vestaron scientific staff may not transfer.

Catalysts and monitorables (next 12 months)

  • Launch of Suterra-branded SPEAR LEP and confirmation of supply continuity (2026)

  • Whether the ADM manufacturing agreement transfers to Suterra or is replaced

  • 2026–2027 EU EUA renewals and progress of the EU full-approval dossier

  • Commercial launch status of BASIN FLEX under Suterra

  • Any formal dissolution, liquidation or distribution announcement by Vestaron Corporation

  • Retention of Vestaron's R&D team at the Kalamazoo facility

Analyst verdict

Vestaron Corporation is a case study in a pattern common to agricultural biotechnology: scientific and regulatory success that did not translate into a standalone business. Over two decades, the company turned a spider-venom peptide concept from the University of Connecticut into two EPA-registered active ingredients. It earned a new IRAC mode-of-action class, product registrations in the United States, Canada and Mexico, and repeat emergency authorisations across four EU member states. Few biological start-ups clear these hurdles. Its products had a strong regulatory profile (0-day PHI, 4-hour REI, MRL exemption), were priced at parity with synthetics, and had been used on more than one million acres.

The commercial and financial record is much weaker, and largely opaque. Vestaron never disclosed revenue or profitability. It raised more than USD 200 million across numerous rounds and went through four CEO transitions. Its EU growth was capped by a regulatory process that the company itself called unfit for peptides. Its 2025 raise, smaller than the 2022 Series C, and the elevation of its CFO to CEO pointed to runway management rather than expansion. The sale of all product lines, actives, pipeline and R&D assets to Suterra in May 2026 should be read as a strategic exit by a company that could not scale independently. Whether that exit created value for shareholders cannot be assessed, because the price was not disclosed.

For institutional readers, Vestaron Corporation itself is no longer an investable or partner-relevant operating entity. The relevant counterparty for SPEAR, BASIN and the peptide pipeline is now Suterra and The Wonderful Company. The technology's long-term value depends on Suterra's ability to secure full EU approval, launch BASIN, and break into broad-acre markets. Verdict: technology validated; independent company concluded; monitor via Suterra.


SOURCE LIST (primary references used)

  • Suterra press release, "Suterra Acquires Vestaron's R&D Assets and Product Lines," 6 May 2026 (suterra.com); coverage in CropLife, Spudman, Fruit Growers News, FreshPlaza, AgriBusiness Global, Good Fruit Grower (May–Jul 2026)

  • The Packer, "Suterra Vestaron Acquisition Signals Transition From the Chemistry Boom to the Biotechnology Boom," 5 Jun 2026

  • vestaron.com (product menu, country sites, acquisition banner), accessed Oct 2026

  • GlobeNewswire / partner reposts: ADM agreement (15 Oct 2024); Portugal EUA (8 Jul 2025); Greece/Italy EUAs (22 Jul 2025)

  • Global Agriculture: CEO transition (2 Feb 2024); BASIN Mexico (22 Mar 2024)

  • HortiDaily: Estupinan permanent CEO (2024)

  • AgriBusiness Global: Collins chair (2023); BASIN Mexico; Capua BioServices; SPEAR RC

  • Vegetable Growers News / Produce Processing: EUAs (2024–2025); Mexico approval (Nov 2021)

  • IBMA: Bernard Blum Award decade interview (2025)

  • Novo Holdings: Series B-1 (16 Feb 2021); Global AgInvesting and NCBiotech: Series C (2022)

  • AgFunderNews / Global AgInvesting: Series B (2019); MEDC (Apr 2019); Xconomy (2012–2014); Global Venturing (Jan 2014); GlobeNewswire (Sep 2011); WMed news archive

  • Aggregators (lower reliability, flagged in text): Preqin, Dealroom, Owler, Techleap/citybiz, i3/Cleantech Group, kscope, sp-edge

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / notes

Juan Estupinan

CEO & President; Board member; CFO & Treasurer

Joined as CFO May 2022; interim CEO Feb 2024; permanent CEO 2024

Described as having financial and business leadership experience across multiple industries

Ben Cicora

SVP Sales & Marketing (title as of 2021–2023)

—

Led Mexico launch and SPEAR RC launch

Dayna Collett, PhD

Senior Manager, Field Development (2023)

—

Presented SPEAR row-crop data

Executive Leadership Team — Steven Hartmeier

NameTenureContext

Steven Hartmeier

2011–2013 (approx.)

Ex-President of Suterra (notable link to the eventual acquirer)

John C. Sorenson, PhD

Interim from Sep 2013; CEO from Jan 2014; died in office (c. Feb 2018)

Took Vestaron from R&D start-up to first product launch

Anna Rath

c.2019 – 2 Feb 2024

Led commercial launch of SPEAR and the 2019–2022 fundraising. Departure not explained publicly

Board of Directors

NameRoleAffiliation / backgroundSince

James C. Collins Jr.

Chair; Executive Director

Former CEO of Corteva. Led the creation and spin-out of Corteva from the Dow/DuPont merger. More than 35 years in agriculture

Board Jan 2023; Chair May 2023

Juan Estupinan

Director

CEO

2024

Randy C. Papadellis

Director

Former President & CEO, Ocean Spray Cranberries

—

Adam Wieschhaus

Director (as of 2021)

Director, Northpond Ventures

Feb 2021

Board observers (2022)

Ariel Barack (Ordway), Mike Wilbur (Cavallo/Wilbur-Ellis), Craig Herron (iSelect)

Series C investors

May 2022

Major Shareholders

InvestorTypeFirst known participation

Novo Holdings

Life-science investor (Denmark)

2019 (led Series B)

Northpond Ventures

Venture capital

2021 (led B-1)

Ordway Selections

Investor

2022 (co-led Series C)

Cavallo Ventures (Wilbur-Ellis)

Corporate venture

2,021

Syngenta Ventures

Corporate venture

By 2021

CGC Ventures (Continental Grain)

Corporate venture

By 2021

Anterra Capital

Venture capital (Rabobank / FIL-backed)

c.2014–2016

Cultivian Sandbox Ventures

Venture capital

By mid-2010s

Open Prairie Ventures

Venture capital

By 2012

Pangaea Ventures

Venture capital

2,012

iSelect

Venture capital

By 2022

Agronautic Ventures, Fortistar, Endeavor8

Investors

2,022

Grosvenor Food & AgTech

Investor

2022 (USD 10M)

SW Michigan First Life Science Fund; Michigan Strategic Fund; Michigan Accelerator Fund

Regional / public funds

2007–2012

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning vs. Vestaron

Corteva Agriscience (spinosyns: spinosad, spinetoram)

Lepidoptera in specialty crops

Incumbent at the same receptor (different site). Scale leader

Bayer Crop Science

Synthetic and biological insecticides

Scale, channel power

Syngenta (incl. Syngenta Biologicals)

Lepidoptera, greenhouse

Also an investor in Vestaron (Syngenta Ventures)

BASF

Insecticides

Broad portfolio

FMC

Diamides (lepidopteran leaders)

Incumbent synthetic standard in many Vestaron crops

Certis Biologicals (Mitsui)

Bt and biological insecticides

Direct competitor in Bt and biological lepidopteran control

Marrone Bio (now part of Bioceres)

Biological insecticides

Biological peer

Biotalys (Belgium, listed)

Protein-based biocontrols

Closest technology analogue (proteins/peptides)

GreenLight Biosciences

RNA-based insecticides

Next-generation biological modality

Provivi

Pheromones

Biological, but a different modality

Suterra (acquirer)

Pheromones / mating disruption

Former competitor for biological spend; now owner

Recent Developments

To meet the minimum entry count, the register extends back to January 2024 for context and marks the window boundary.

Company Snapshot

25

Employees

$410M

Market Cap

2005

Founded

MI, US

Headquarters

SWOT Analysis

Strengths

  • Novel IRAC classification. IRAC Group 32 gives a resistance-management role that synthetics cannot fill (IRAC; 2019 releases).
  • Two registered actives. SPEAR (EPA 2018) and BASIN (EPA unconditional registration, Mar 2024).
  • Grower-friendly label. 4-hour REI, 0-day PHI and MRL exemption across products.
  • Demonstrated adoption. More than 1M acres treated by March 2025; 5% California pistachio share in 2021.
  • Strong strategic investor syndicate. Novo Holdings, Syngenta Ventures, Cavallo/Wilbur-Ellis, CGC.
  • High-calibre governance. Former Corteva CEO as chair; former Ocean Spray CEO on the board.

Weaknesses

  • No disclosed profitability. Repeated fundraising (more than USD 130M in 2021–2022) indicates sustained cash burn.
  • Leadership instability. Four CEO transitions between 2011 and 2024, including one CEO's death in office.
  • Narrow spectrum. SPEAR LEP is designed for tank-mixing with Bt and is focused mainly on Lepidoptera.
  • Outsourced manufacturing. Reliance on Capua, then ADM, exposed the company to COGS and supply risk.
  • Timeline slippage. BASIN FLEX was targeted for a Q4 2022 U.S. launch but was only registered in March 2024.
  • EU access limited to EUAs. Sales were restricted to one crop and pest for about 120 days at a time.

Opportunities

  • EU full approval. Hoped for in 2027 (IBMA). This would unlock the whole EU market.
  • Broad-acre crops. SPEAR RC in cotton and soybean; Suterra sees interest in corn and cotton (The Packer, 2026).
  • Brazil. Regulators there are reforming the framework to speed biological approvals.
  • Pipeline across six receptors. Could provide multiple future modes of action.
  • Rotation and IPM stacking. Combination with pheromones (Suterra CheckMate DBM-F plus SPEAR LEP).
  • Synthetic withdrawals. Neonicotinoid restrictions in the EU create vacated market share.

Threats

  • Lost independence. The May 2026 asset sale ends Vestaron's standalone upside.
  • Peptide competition. Large-company biological programmes and protein-based peers (e.g., Biotalys).
  • EU regulation. The process remains slow and complex for peptides, according to the company.
  • Customer scepticism. Grower doubts about biological consistency remain, though Suterra says these are fading.
  • Supply chain and tariffs. Volatility affects input availability (Suterra comments, 2026).
  • Incumbent price pressure. Generic synthetics compete against a product priced at parity with them.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 Feb 2024CEO Anna Rath departs; CFO Juan Estupinan named interim CEOLeadership reset; finance-led management
Feb 2024Greece grants first EUA for SPEAR LEP on tomatoes (1 Mar–28 Jun window)First European sales
Early Mar 2024EPA unconditional registration of BASINSecond active registered
22 Mar 2024COFEPRIS registers BASIN active in MexicoSecond active outside the U.S.
Mar 2024Italy EUA (28 Mar–25 Jul)Second EU country
May 2024Cyprus EUA (2 May–29 Aug)Third EU country
2024Estupinan made permanent CEO and board member. Board cites market penetration in focus regions and EU developmentLeadership stabilised
15 Oct 2024ADM long-term manufacturing agreementSupply and COGS
6 Mar 2025Second-cycle EUAs in Italy, Greece and Cyprus (120-day windows)Repeat EU demand
27 Mar 2025More than USD 20M financing; more than 1M acres treated citedRunway extension
2025IBMA interview: EU dossier filed 2022; full approval hoped for 2027; pricing at parity with syntheticsRegulatory timeline disclosed
18-month window begins (Apr 2025)—–
8 Jul 2025Portugal EUA for SPEAR LEP on tomatoes; Lainco partnershipFourth EU country; Iberian channel
22 Jul 2025Fourth Greek EUA (tomato, through 19 Nov)Recurring access
22 Jul 2025First Italian EUA on olives against olive moth (through 8 Oct)First new crop/pest in the EU
22 Jul 2025Active EUAs across four EU countries and two cropsPeak EU footprint
6 May 2026Suterra announces acquisition of Vestaron product lines, actives, pipeline and Kalamazoo R&D assetsExit; end of independent operations
6 May 2026Suterra plans to manufacture its own branded SPEAR LEP later in 2026Brand and supply transition
6 May 2026Estupinan publicly endorses the transactionManagement alignment with sale
8 May 2026AgriBusiness Global carries the transaction announcementIndustry coverage
11 May 2026Spudman and Fruit Growers News report the dealGrower-market coverage
5 Jun 2026The Packer: Suterra outlines integration into IPM programmes with pheromones, use of its Europe/Africa registrations, and interest in corn and cottonIntegration strategy
Jul 2026Good Fruit Grower covers the acquisitionTree-fruit channel awareness
2026 (accessed Oct)Vestaron website adds banner noting Suterra's acquisition of certain assets and product rights; news page password-protectedPublic-facing wind-down signal
Oct 2026No announced dissolution, layoffs (WARN) or further financing foundEntity status unresolved
Oct 2026Italian olive EUA window (to 8 Oct 2025) and other 2025 EUAs have lapsed; 2026 EUA renewals under Suterra n/dMonitorable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (%): SPEAR share of California pistachio insecticide market rose from 3% in FY2020 to 5% in FY2021.
Vestaron Corporation — Revenue by Segment (%)
Series (%)FY2020FY2021
SPEAR share of California pistachio insecticide market35

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.